Oridonin alleviates visceral hyperalgesia in a rat model of postinflammatory irritable bowel syndrome: Role of colonic enterochromaffin cell and serotonin availability

Journal of Medicinal Food

Volumn 19, Issue 6, 2016, Pages 586-592

  Zang, Kai Hong ^a   Shao, Yun Yun ^b   Zuo, Xiao ^b   Rao, Zhi ^b   Qin, Hong Yan ^b  

^a GANSU UNIVERSITY OF CHINESE MEDICINE   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

colonic cytokine production; enterochromaffin cell; oridonin; postinflammatory irritable bowel syndrome; serotonin

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 4; ORIDONIN; SEROTONIN; TRINITROBENZENESULFONIC ACID; TRYPTOPHAN HYDROXYLASE; TUMOR NECROSIS FACTOR ALPHA; KAURANE DERIVATIVE; TUMOR NECROSIS FACTOR;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL HYPERPLASIA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MEGADOSE; ENTEROCHROMAFFIN CELL; HYPERALGESIA; IRRITABLE COLON; LOW DRUG DOSE; MALE; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT MODEL; SPLEEN; THYMUS; VISCERAL HYPERALGESIA; WITHDRAWAL REFLEX; ANIMAL; COLON; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; HUMAN; IRRITABLE BOWEL SYNDROME; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; COLON; DISEASE MODELS, ANIMAL; DITERPENES, KAURANE; ENTEROCHROMAFFIN CELLS; HUMANS; HYPERALGESIA; INTERFERON-GAMMA; INTERLEUKIN-4; IRRITABLE BOWEL SYNDROME; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84974602745     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2015.3595     Document Type: Article

References (27)

1. Yao X, Yang YS, Cui LH, et al.: Subtypes of irritable bowel syndrome on Rome III criteria: A multicenter study. J Gastroenterol Hepatol 2012;4:760-765.
2. Spiller RC, Garsed K: Postinfectious irritable bowel syndrome. Gastroenterology 2009;6:1979-1988.
3. Thabane M, Marshall JK: Post-infectious irritable bowel syndrome. World J Gastroenterol 2009;29:3591-3596.
4. Shen YH, Nahas R: Complementary and alternative medicine for treatment of irritable bowel syndrome. Can Fam Physician 2009; 2:143-148.
5. Kim DY, Camilleri M: Serotonin: A mediator of the brain-gut connection. Am J Gastroenterol 2000;10:2698-2709.
6. Bertrand PP, Bertrand RL: Serotonin release and uptake in the gastrointestinal tract. Auton Neurosci 2010;1-2:47-57.
7. Mawe GM, Coates MD, Moses PL: Review article: Intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther 2006;8:1067-1076.
8. El-Salhy M, Hatlebakk JG, Gilja OH, Hausken T: Irritable bowel syndrome: Recent developments in diagnosis, pathophysiology, and treatment. Expert Rev Gastroenterol Hepatol 2014;4:435-443.
9. Spiller RC: Serotonin and GI clinical disorders. Neuropharmacology 2008;6:1072-1080.
10. Wang H, Steeds J, Motomura Y, et al.: CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut 2007;7:949-957.
11. Motomura Y, Ghia JE, Wang H, et al.: Enterochromaffin cell and 5-hydroxytryptamine responses to the same infectious agent differ in Th1 and Th2 dominant environments. Gut 2008;4:475-481.
12. Qin HY, Cheng CW, Tang XD, Bian ZX: Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol 2014;39:14126-14131.
13. Brown PM, Drossman DA, Wood AJ, et al.: The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology 2011;2:507-516.
14. Li CY, Wang EQ, Cheng Y, Bao JK: Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int J Biochem Cell Biol 2011;5:701-704.
15. Xu Y, Xue Y, Wang Y, et al.: Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-Activated microglia. Int Immunopharmacol 2009;3:360-365.
16. Zang KH, Du LD, Liu XM, et al.: Therapeutic effect of oridonin trablet on acetic acid-induced ulcerative colitis in mice. Chin JMAP 2012;9:781-785.
17. Qin HY, Xiao HT, Wu JC, et al.: Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats. World J Gastroenterol 2012;20: 2481-2492.
18. Al-Chaer ED, Kawasaki M, Pasricha PJ: A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000; 5:1276-1285.
19. Zheng X, Kang A, Dai C, et al.: Quantitative analysis of neurochemical panel in rat brain and plasma by liquid chromatographytandem mass spectrometry. Anal Chem 2012;22:10044-10051.
20. Spiller RC, Jenkins D, Thornley JP, et al.: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;6:804-811.
21. Dunlop SP, Jenkins D, Neal KR, Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003;6:1651-1659.
22. Kerckhoffs AP, Ter Linde JJ, Akkermans LM, Samsom M: Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil 2008;8: 900-907.
23. Coates MD, Mahoney CR, Linden DR, et al.: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004;7:1657-1664.
24. Wheatcroft J, Wakelin D, Smith A, et al.: Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 2005;6:863-870.
25. Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo JJ: Irritable bowel syndrome immune hypothesis. Part II: The role of cytokines. Rev Esp Enferm Dig 2010;12:711-717.
26. Wang S, Zhang Y, Saas P, et al.: Oridonins therapeutic effect: Suppressing Th1/Th17 simultaneously in a mouse model of Crohns disease. J Gastroenterol Hepatol 2015;3:504-512.
27. Yang YC, Wei MC, Huang TC: Optimisation of an ultrasoundassisted extraction followed by RP-HPLC separation for the simultaneous determination of oleanolic acid, ursolic acid and oridonin content in Rabdosia rubescens. Phytochem Anal 2012; 6:627-636.